Imidazoquinoline TLR7/8 Agonists with Hyaluronan-Tocopherol Carriers
Solution Overview
Problem
Current treatments for superficial basal cell carcinoma, actinic keratosis, cutaneous T-cell lymphoma, and melanoma are limited in efficacy and specificity, and there is a need for more effective agents that can target these conditions without significant side effects.
Innovation Solution
The development of compounds according to Formula I, or their pharmaceutically acceptable salts, which act as agonists for TLR7 and/or TLR8 receptors, are used in pharmaceutical compositions to treat cancers and as vaccine adjuvants. These compounds are formulated with a hyaluronan-tocopherol conjugate to enhance their therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for superficial basal cell carcinoma, actinic keratosis, cutaneous T-cell lymphoma, and melanoma are used, then treatment is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies the chemical structure of known TLR7/8 agonists by changing parameters such as substituting the imidazoquinoline core with triazolo[4,3-a]pyridine or pyrimido[5,4-d]pyrimidine rings, and varying substituents at different positions to optimize both efficacy and specificity for treating skin cancers and actinic keratosis
Solution Approach 2:
The invention creates composite pharmaceutical compositions by combining the novel TLR7/8 agonist compounds with hyaluronan-tocopherol conjugates, forming a composite delivery system that enhances therapeutic efficacy while reducing side effects through targeted delivery to affected tissues
2Reliability
If current treatments are used, then treatment is provided, but side effects are significant
Solution Approach 1:
The patent introduces hyaluronan-tocopherol conjugates as intermediary carriers that mediate the delivery of TLR7/8 agonist compounds to target tissues, reducing systemic exposure and thereby minimizing side effects while maintaining local treatment effectiveness
Solution Approach 2:
The invention uses hyaluronan, a naturally occurring biomaterial, as a carrier that mimics the extracellular matrix environment, allowing for biocompatible and biodegradable delivery systems that reduce adverse reactions compared to synthetic carriers
Data Source
AI summary
The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.



